AlzeCure Pharma develops novel analgesic drug based on Nobel prize-winning discoveries
Stockholm, Sweden, October 6, 2021. AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company that develops a broad portfolio of candidate drugs for diseases affecting the central nervous system, with projects in both Alzheimer’s disease and pain, today announced that the its novel clinical candidate drug ACD440 for peripheral neuropathic pain, is based on the seminal discoveries of TRPV1 by Prof. Julius, and for which he was awarded the Nobel Prize in Medicine 2021.David Julius, PhD, professor and chair of the Department of Physiology and Morris Herzstein Chair in Molecular